Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Epigenetics

Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities

  1. 1Department of Urology, Chongqing Jiulongpo People’s Hospital, Chongqing, China

Abstract

Urothelial bladder cancer (UBC) is a molecularly heterogeneous malignancy characterized by frequent recurrence, variable progression, and treatment resistance. In addition to recurrent genetic alterations, dysregulation of chromatin remodeling, histone modifications, DNA methylation, and enhancer activity contributes to the biological diversity of UBC. This narrative review critically evaluates the role of epigenetic reprogramming in UBC and integrates mechanistic evidence with biomarker development and therapeutic investigation. Recurrent alterations involving ARID1A, KDM6A, KMT2C/KMT2D, EP300, and CREBBP can modify chromatin accessibility and transcriptional programs, although the functional consequences and strength of causal evidence vary among regulators. Preclinical studies have identified therapeutically relevant dependencies, including the relationship between KDM6A loss, PRC2-mediated repression, and EZH2 inhibition, but clinical validation of most epigenetic targets remains limited. DNA methylation represents the most extensively investigated epigenetic biomarker class in UBC. Urine-based methylation assays have shown encouraging diagnostic performance, whereas plasma cell-free DNA methylation remains an emerging approach requiring further prospective validation. Clinical studies of epigenetic therapies have produced mixed results, emphasizing the need to distinguish biological rationale from demonstrated therapeutic efficacy. Collectively, current evidence supports epigenetic alterations as important contributors to UBC biology while highlighting the need for functional validation, biomarker-selected trials, and longitudinal epigenomic studies before routine clinical implementation.

Related

  1. Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
    Zhibo Zhang, Jie Liu, Guofeng Lei +1
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCPMC
  2. Microbiome-mitochondria crosstalk in neuro-oncology: molecular mechanisms, immunometabolic reprogramming, and therapeutic opportunities
    Debabrata Dash, Muskan Rajak, Priyanka Manothiya +1
    Frontiers in MicrobiomesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationPMC
  3. Crosstalk between IL-6/JAK/STAT3 and TNF-α/NF-κB signaling in colitis-associated colorectal cancer: epigenetic reprogramming, evidence boundaries, and opportunities for disease management
    Jin Yuan, Jinping Liao, Fen Li +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefPMCEurope PMC
  4. Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities
    Tuya Wang, Jing Fu, Ye Huang +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. Peroxiredoxins in disease biology: molecular mechanisms and therapeutic opportunities
    Yunjia Jiang, Xin Yao, Xuqi Sun +3
    Frontiers in molecular biosciencesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
BibTeX
@article{yuanjiang2026epigenetic,
  title = {{Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities}},
  author = {Qian Yuanjiang and Yang Liming},
  journal = {Epigenetics},
  year = {2026},
  month = nov,
  doi = {10.1080/15592294.2026.2753250},
  url = {https://doi.org/10.1080/15592294.2026.2753250},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities
AU  - Qian Yuanjiang
AU  - Yang Liming
PY  - 2026
DA  - 2026/11/07
JO  - Epigenetics
DO  - 10.1080/15592294.2026.2753250
UR  - https://doi.org/10.1080/15592294.2026.2753250
AB  - Urothelial bladder cancer (UBC) is a molecularly heterogeneous malignancy characterized by frequent recurrence, variable progression, and treatment resistance. In addition to recurrent genetic alterations, dysregulation of chromatin remodeling, histone modifications, DNA methylation, and enhancer activity contributes to the biological diversity of UBC. This narrative review critically evaluates the role of epigenetic reprogramming in UBC and integrates mechanistic evidence with biomarker development and therapeutic investigation. Recurrent alterations involving ARID1A, KDM6A, KMT2C/KMT2D, EP300, and CREBBP can modify chromatin accessibility and transcriptional programs, although the functional consequences and strength of causal evidence vary among regulators. Preclinical studies have identified therapeutically relevant dependencies, including the relationship between KDM6A loss, PRC2-mediated repression, and EZH2 inhibition, but clinical validation of most epigenetic targets remains limited. DNA methylation represents the most extensively investigated epigenetic biomarker class in UBC. Urine-based methylation assays have shown encouraging diagnostic performance, whereas plasma cell-free DNA methylation remains an emerging approach requiring further prospective validation. Clinical studies of epigenetic therapies have produced mixed results, emphasizing the need to distinguish biological rationale from demonstrated therapeutic efficacy. Collectively, current evidence supports epigenetic alterations as important contributors to UBC biology while highlighting the need for functional validation, biomarker-selected trials, and longitudinal epigenomic studies before routine clinical implementation.
SN  - 1559-2294
SN  - 1559-2308
ER  -